| UNITED STATES |
| SECURITIES AND EXCHANGE COMMISSION |
| Washington, D.C. 20549 |
| |
| FORM 8-K |
| |
| Current Report |
| Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 |
| |
| Date of Report (Date of earliest event reported):May 6, 2016 |
| |
| ANAVEX LIFE SCIENCES CORP. |
| (Exact name of registrant as specified in its charter) |
| Nevada | 000-51652 | 98-0608404 |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |
| 51 W 52nd Street, 7th floor, New York, NY 10019-6163 |
| (Address of principal executive offices and Zip Code) |
| |
| Registrant's telephone number, including area code1-844-689-3939 |
| |
| N/A |
| (Former address) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
| Item 7.01 | Regulation FD Disclosure. |
Attached asExhibit 99.1 to this Current Report on Form 8-K is a corporate presentation that will be delivered by Anavex Life Sciences Corp., a Nevada corporation (the “Company”), on May 6, 2016, at the Annual Meeting of Stockholders of the Company.
The information in this Current Report on Form 8-K (includingExhibit 99.1) is being furnished solely to satisfy the requirements of Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit Number | | Description |
| | | |
| 99.1 | | Corporate Presentation. |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | ANAVEX LIFE SCIENCES CORP. |
| | |
| | /s/ Christopher Missling, Ph.D. |
| | Name: Christopher Missling. Ph.D. |
| | Title: Chief Executive Officer |
| | Date: May 6, 2016 |
